Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | PLOD2 | O00469 | 1/20 | 0.40 |
| ▸ | PLOD3 | O60568 | 1/20 | 0.40 |
| ▸ | PLOD1 | Q02809 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | ESR1 | P03372 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2453510 | 0.89 | TSHR (0.52) | TP53TSHRL3MBTL1KMT2ANPC1 | |
| SCHEMBL8964823 | 0.89 | TSHR (0.52) | TP53TSHRL3MBTL1KMT2ANPC1 | |
| SCHEMBL8263643 | 0.84 | ALDH1A1 (0.44) | KMT2ANCOA3ALDH1A1LMNASLC6A4 | |
| SCHEMBL7228870 | 0.83 | CYP1A2 (0.52) | L3MBTL1KMT2ANPC1RAB9AMEN1 | |
| SCHEMBL11170355 | 0.80 | L3MBTL1 (0.45) | TP53TSHRL3MBTL1KMT2ANPC1 | |
| SCHEMBL9738786 | 0.78 | KMT2A (0.48) | TP53TSHRKMT2ANPC1RAB9A | |
| SCHEMBL7262891 | 0.77 | CES2 (0.49) | TP53TSHRKMT2ANPC1RAB9A | |
| SCHEMBL8964973 | 0.77 | MAPT (0.60) | KMT2ANPC1RAB9AMEN1ALDH1A1 | |
| SCHEMBL8965070 | 0.74 | CES1 (0.49) | KMT2AMEN1ALDH1A1ESR1ESR2 | |
| SCHEMBL10769769 | 0.74 | TP53 (0.46) | TP53TSHRL3MBTL1KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6645989-B2 | Antiinflammatory agents | SMITHKLINE BEECHAM CORPORATION | 2003-11-11 | — | — | US | disclosed |
| US-20030064997-A1 | Novel compounds | SMITHKLINE BEECHAM CORPORATION | 2003-04-03 | — | — | US | disclosed |
| US-6268370-B1 | CYTOKINE MEDIATED DISEASES | SMITHKLINE BEECHAM CORPORATION | 2001-07-31 | — | — | US | disclosed |
| US-5916891-A | CYTOKINE MEDIATED DISEASES | SMITHKLINE BEECHAM CORPORATION (US) | 1999-06-29 | — | — | US | disclosed |
| US-5686455-A | Imidazole derivatives and their use as cytokine inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 1997-11-11 | — | — | US | disclosed |
| US-5656644-A | CYTOKINE SUPPRESSORS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-08-12 | — | — | US | disclosed |
| EP-0623126-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1994-11-09 | — | — | EP | disclosed |
| EP-0231622-B1 | Inhibition of the 5-lipoxygenase pathway | SMITHKLINE BEECHAM CORP (US) | 1994-08-24 | — | — | EP | disclosed |
| EP-0321490-B1 | INHIBITION OF INTERLEUKIN-1 PRODUCTION BY MONOCYTES AND/OR MACROPHAGES | SMITHKLINE BEECHAM CORP (US) | 1994-06-22 | — | — | EP | disclosed |
| WO-1993014081-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1993-07-22 | — | — | WO | disclosed |
| US-5134150-A | Administering diaryl-substituted imidazothiazoles; antiarthritic agents | SMITHKLINE BEECHAM CORPORATION (US) | 1992-07-28 | — | — | US | disclosed |
| EP-0321490-A4 | INHIBITION OF INTERLEUKIN-1 PRODUCTION BY MONOCYTES AND/OR MACROPHAGES. | SMITHKLINE BECKMAN CORP (US) | 1990-05-14 | — | — | EP | disclosed |
| EP-0321490-A1 | INHIBITION OF INTERLEUKIN-1 PRODUCTION BY MONOCYTES AND/OR MACROPHAGES. | SMITHKLINE BECKMAN CORP (US) | 1989-06-28 | — | — | EP | disclosed |
| WO-1988001167-A1 | INHIBITION OF INTERLEUKIN-1 PRODUCTION BY MONOCYTES AND/OR MACROPHAGES | SMITHKLINE BECKMAN CORPORATION (US) | 1988-02-25 | — | — | WO | disclosed |
| WO-1988001169-A1 | INHIBITION OF INTERLEUKIN-1 PRODUCTION BY MONOCYTES AND/OR MACROPHAGES | SMITHKLINE BECKMAN CORPORATION (US) | 1988-02-25 | — | — | WO | disclosed |
| EP-0231622-A2 | Inhibition of the 5-lipoxygenase pathway | SMITHKLINE BEECHAM CORPORATION (US) | 1987-08-12 | — | — | EP | disclosed |
| EP-0011111-B1 | 5-(4-PYRIDYL)-6-(4-FLUOROPHENYL)-2,3-DIHYDROIMIDAZO-(2,1-B)-THIAZOLE, PROCESS FOR ITS PREPARATION AND MEDICAL COMPOSITION | SMITHKLINE BECKMAN CORPORATION (US) | 1982-09-22 | — | — | EP | disclosed |
| US-4175127-A | ANTIARTHRITIC AGENTS | SMITHKLINE CORPORATION (US) | 1979-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030064997-A1 | Novel compounds | BRD4, BRDT, HDAC6 | TP53 640/4885TSHR 3313/4885L3MBTL1 3052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.